Best Cardiac and Vascular Disorders Companies in Ontario, Canada
The 36 best Cardiac and Vascular Disorders companies in Ontario, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Flosonics Medical.
Ranked: Best Cardiac and Vascular Disorders companies in Ontario
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Flosonics Medical Developer of non-invasive hemodynamic monitoring devices 48Funding top 29%Moat top 32%Product top 35%Patents top 39% All 9 signals ▾Fundingtop 29% Moattop 32% Producttop 35% Patentstop 39% Innovationtop 42% Techtop 44% Globalbottom 43% Marketbottom 39% Newsbottom 22% Funding: Raised $39.0M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 22 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $39M | 18 mo ago | 38 | — | WordPressApple iCloud MailGoogle Workspace+37 | 22 patents Wearable ultrasound patches and controllable fluid devices for patient fluid monitoring and therapy | 2 job openings |
| 2 | Conavi A catheter-based ultrasound system for cardiac imaging 48Funding top 24%Growth top 38%News top 38%Partners top 40% All 9 signals ▾Fundingtop 24% Growthtop 38% Newstop 38% Partnerstop 40% Moattop 48% Talentbottom 49% Marketbottom 48% Techbottom 41% Globalbottom 29% Funding: Raised $27.7M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Growth: 2 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $28M | 8 mo ago | 76 | Aman Thind Co-founder and Chief Technology Officer | YouTubeGoogle Cloudstyled-components+6 | — | 1 award |
| 3 | CellAegis Devices A non-invasive, automated device for Chronic Remote Ischemic Conditioning | $10M | 114 mo ago | 5 | — | — | 50 patents Remote ischemic conditioning medical devices and gas‑powered therapeutic systems | — |
| 4 | Matrizyme Pharma Collagenase formulation for chronic total occlusions | $10M | 158 mo ago | — | Bradley Strauss Founder & Chairman | — | — | — |
| 5 | VentriPoint Heart analysis system 62News top 18%Product top 24%Growth top 25%Partners top 32% All 10 signals ▾Newstop 18% Producttop 24% Growthtop 25% Partnerstop 32% Fundingtop 36% Globaltop 37% Techtop 44% Innovationtop 47% Moattop 48% Marketbottom 45% News: 9 BI events in 12 mo (of 46 tracked, 7 types) · +350% YoY Product: 1 product launch event in 12 mo · 12 distinct product lines rank vs industry peers · Fliar Intelligence Index 62/100 | $9M | 19 mo ago | — | — | WordPressMySQLZoho+17 | — | — |
| 6 | Cardiol Therapeutics Developer of anti-inflammatory therapies for heart disease 53News top 24%Growth top 25%Patents top 31%Moat top 32% All 11 signals ▾Newstop 24% Growthtop 25% Patentstop 31% Moattop 32% Innovationtop 34% Fundingtop 37% Talentbottom 49% Techbottom 41% Globalbottom 36% Partnersbottom 35% Marketbottom 33% News: 16 BI events in 12 mo (of 39 tracked, 6 types) · +129% YoY Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $9M | 11 mo ago | 17 | David Elsley President & CEO/Founder | WordPressApple iCloud MailMicrosoft 365+19 | 55 patents Cannabinoid-based therapeutics and polymer micelle formulations for pericarditis and heart failure | 1 award |
| 7 | Pivotal Therapeutics Canadian, commercial-stage biopharma developing highly-purified prescription Omega 3 Therapy for CVD | $8M | 150 mo ago | — | George Jackowski Co-Founder & CSO | — | 44 patents Omega-3 fatty acid pharmaceutical/medical food formulations for cardiovascular disease risk reduction | — |
| 8 | Mannin Research Developer of therapeutics for vascular diseases | $8M | 82 mo ago | 2 | — | — | — | — |
| 9 | Paradox Immunotherapeutics Developer of immunotherapeutics for the treatment of rare diseases | $7M | 18 mo ago | 9 | Yulong Sun Co-Founder | — | 5 patents Monoclonal antibodies specific for conformational epitopes of lambda immunoglobulin light chains | — |
| 10 | Synex Medical Developer of non-invasive health monitoring technology using magnetic resonance spectroscopy | $5M | 70 mo ago | 24 | Ben Nashman Founder & CEO | Apple iCloud MailGoogle WorkspaceSalesforce+11 | 30 patents NMR-based wearable devices for blood analyte measurement and calibration systems | — |
| 11 | CardioComm Solutions Provides software for electrocardiogram (“ECG”) management and reporting software | $4M | 147 mo ago | 23 | Etienne Grima CEO | Cart FunctionalityWooCommerceWordPress+15 | 2 patents Secure unlocking mechanisms for over‑the‑counter biosignal recording devices | — |
| 12 | CardioGenics Develops ultra-sensitive analyzers and immunoassay tests for In-vitro diagnosis | $2M | 187 mo ago | 4 | — | — | 18 patents Patents concentrated in transport & manufacturing processes | — |
| 13 | Event Cardio Group Ambulatory portable cardiac monitoring devices | $295K | 133 mo ago | 11 | John Bentivoglio CEO & President | — | 3 patents Wireless cardiac event monitoring devices for arrhythmia detection and transmission | — |
| 14 | HelpWear Wearable device for cardiac monitoring | $120K | 111 mo ago | 19 | — | — | 12 patents Wearable dry‑electrode ECG monitoring and cardiology sensor technology. | — |
Top 12 Cardiac and Vascular Disorders companies in Ontario
#1
Public · Toronto, Ontario · founded 2007 · 76 employees$27.7Mraised▾
A catheter-based ultrasound system for cardiac imaging. The company has developed, Foresight ICE System, a catheter-based ultrasound system capable of providing both 2D and 3D ultrasound images of cardiac anatomy around the circumference of the catheter's tip.
- Jan 2026Post IPO$700K
- Apr 2025Post IPO$15.5M
- Oct 2024Series B$7.7M
- Dec 2021Series B$20M
#2
Public · Oakville, Ontario · founded 2017 · 17 employees$8.9Mraised▾
Developer of anti-inflammatory therapies for heart disease. It focuses on the research and clinical development of treatments targeting inflammation and fibrosis in conditions like pericarditis, myocarditis, and heart failure. The company's pipeline includes drug candidates currently in clinical trials. Its approach involves understanding the role of inflammation and fibrosis in cardiac diseases to develop therapies promoting healing.
- Oct 2025Post IPO$11M
- Mar 2021Post IPO$10M
- Dec 2020Post IPO$829.1K
- Jan 2019Post IPO$3.7M
#3
Series C · Greater Sudbury, Ontario · founded 2015 · 38 employees$39Mraised▾
Flosonics Medical is a developer of non-invasive sensors for the management of critically ill patients, performing continuous monitoring of arterial flow with automatic artery detection. The company develops products for fluid responsiveness detection in the ICU, E.D, and operating room. The company's smart-bandage product, FloPatch, is designed to address the clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance, emergency department, operating room, and intensive care unit. The patch is disposable and is enabled with ultrasound technology.
- Mar 2025Venture Debt$5.2M
- May 2024Series C$20M
- Feb 2021Series A$14M
- Sep 2019Grant (prize money)—
#4
Public · Toronto, Ontario · founded 2005$9.1Mraised▾
Ventripoint Diagnostics is a medical device company that develops and commercializes its diagnostic tools to monitor patients with heart disease. By using images produced from existing medical imaging systems, the Ventripoint Medical System (VMS), an FDA cleared device, generates heart volumetric measurements and a three-dimensional (3D) model. Its solution produces heart information by processing information received from existing medical imaging equipment with its patented and own methods incorporating Knowledge-Based Reconstruction (KBR) algorithms and own cardiac databases. Its KBR method allows for the creation of a 3D model of the right and/or left ventricle using images generated from existing two-dimensional imaging equipment.
- Feb 2025Post IPO$60.7K
- Jan 2025Post IPO$117.3K
- Dec 2024Post IPO$239.5K
- Nov 2024Post IPO$13.8K
#5
Series A · Toronto, Ontario · founded 2019 · 9 employees$7Mraised▾
Developer of immunotherapeutics for the treatment of rare diseases. The company has a drug design platform to develop monoclonal antibody (mAb) treatment for protein misfolding diseases. The drug pipeline inlcudes LX-96 for heart failure, KX-99 for ALECT2 amyloidosis, and NX-86 for neurodegenerative diseases.
- Feb 2025Series A$7M
#6
Series C · Mississauga, Ontario · founded 2009 · 5 employees$9.6Mraised▾
CellAegis Devices is developing the autoRIC device, a non-invasive, portable and automated device, for Chronic Remote Ischemic Conditioning (CRIC - brief episodes of no blood flow in a limb followed by resumed blood flow) following Acute Myocardial Infarction. The autoRIC device provides point-of-care delivery of RIC. It is intended to provide RIC to adult patients over 18 years of age undergoing cardiothoracic surgery or interventional cardiothoracic procedures or patients with evolving myocardial infarction. The device has received CE Mark and Health Canada approval but an investigational device in the US as of January 2018.
- Mar 2017Series C$9.5M
- Mar 2016Seed$81.1K
- Jul 2013Seed—
- Mar 2013Seed$23.7K
#7
Acquired · Toronto, Ontario · founded 2012 · 2 employees$7.5Mraised▾
Mannin Research is developing therapeutics for vascular diseases. Their lead candidate, MAN-01, is for the treatment of Primary Open Angle Glaucoma and is in pre-clinical stages. MAN-01 is a small molecule, formulated as an eye drop, to reduce intraocular eye pressure (IOP) (risk factor in Glaucoma progression). The second candidate is indicated for cystic kidney disease and is in discovery stages.
- Nov 2019Grant (prize money)$7.5M
- Nov 2017Grant (prize money)—
#8
Seed · Toronto, Ontario · founded 2017 · 24 employees$5.3Mraised▾
Developer of non-invasive health monitoring technology using magnetic resonance spectroscopy. The technology measures blood metabolites like glucose and lactate without a needle prick. It uses magnetic resonance to measure hydrogen atoms in metabolites. Radio frequency pulses target protons in glucose molecules, enhancing signals. The technology isolates and measures analyte signals to determine blood concentrations.
- Oct 2020Seed$5.3M
#9
Series A · Richmond Hill, Ontario · founded 2010$9.5Mraised▾
Matrizyme is focussed on developing therapeutics in the area of interventional cardiology. Its lead candidate MZ-004 is an enzyme formulation of collagenase that is administered locally by injection directly into the proximal fibrous cap of the occlusion where it degrades the collagen within the occluded lumen. The candidate has finished phase 1 clinical study in 2012 and is currently in phase 2 trials for chronic total occlusions (CTOs).
- Jun 2013Series A$9.5M
#10
Public · Vaughan, Ontario · founded 2010$7.7Mraised▾
Pivotal Therapeutics is a Canadian, commercial-stage biopharma developing highly-purified prescription Omega 3 Therapy for CVD. In Feb 2016, it announced US patent for stabilization of vulnerable plaque using a combination of statin and Omega 3 fatty acids. The company has one prescription product and 2 OTC products. The prescription product is VASCAZEN, indicated for Omega-3 Deficiency in cardiovascular patients. The product was clinically shown to correct an Omega-3 Deficiency in CVD Patients, with an associated 48% reduction in triglycerides and a rise in HDL-C without negative impact on the LDL-C lipid profile in the 8-week treatment period. The 2 OTC Products are OMAZEN and BENEFISHIAL.
- Mar 2014Conventional Debt$7.7M
#11
Public · Toronto, Ontario · founded 1989 · 23 employees$3.9Mraised▾
CardioComm Solutions’ specializes in the software engineering of computer based electrocardiogram (“ECG”) management and reporting software. This software permits physician interpretations of ECGs and supports private and public payer fee-for-service billings. CardioComm Solutions offerings include PC and LAN based products known as GEMS( Global ECG Management System), internet based SAAS and ASP software is known as GC3/12 (Global Cardio 3 and 12 lead), a medical ECG service (call centre model) is operated under the C4 name (CardioComm Solutions Coordinating Centre) and a consumer based HeartCheck driven call centre under the Smart Monitoring name
- 2014Post IPO—
- Feb 2012Post IPO$2M
- Feb 2011Post IPO$150K
- Dec 2010Post IPO$300K
#12
Public · Mississauga, Ontario · founded 1997 · 4 employees$1.9Mraised▾
CardioGenics develops ultra-sensitive analyzers and immunoassay tests for IVD testing. The company's QL Care analyzer, is an immunoassay point-of-care analyzer for IVD testing. The company has also developed a proprietary method for silver coating paramagnetic microspheres to help improve instrument sensitivity to light. This technology is deployed in CardioGenics’ POC platform. Immunoassay tests include: Troponin I Test, Plasminogen Activator Inhibitor Type-1 Test, Heart Failure Risk Stratification and Heart Failure Genomics Risk.
- Feb 2011Post IPO$1.9M
- Aug 2009Post IPO$2.7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.